These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18027227)

  • 61. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Innovative approaches for designing and analyzing adaptive dose-ranging trials.
    Bornkamp B; Bretz F; Dmitrienko A; Enas G; Gaydos B; Hsu CH; König F; Krams M; Liu Q; Neuenschwander B; Parke T; Pinheiro J; Roy A; Sax R; Shen F
    J Biopharm Stat; 2007; 17(6):965-95. PubMed ID: 18027208
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Robustness of an odds-ratio test in a stratified group sequential trial with a binary outcome measure.
    Srivastava DK; Rai SN; Pan J
    Biom J; 2007 Jun; 49(3):351-64. PubMed ID: 17623341
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Standard versus adaptive monitoring procedures: A commentary.
    Fleming TR
    Stat Med; 2006 Oct; 25(19):3305-12; discussion 3313-4, 3326-47. PubMed ID: 16850447
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Two-stage design of clinical trials involving recurrent events.
    Cook RJ; Bergeron PJ; Boher JM; Liu Y
    Stat Med; 2009 Sep; 28(21):2617-38. PubMed ID: 19579215
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Group sequential and discretized sample size re-estimation designs: a comparison of flexibility.
    Wu X; Cui L
    Stat Med; 2012 Oct; 31(24):2844-57. PubMed ID: 22733405
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Problems raised by interim analysis in therapeutic trials].
    Rodary C; Nougue CC
    Bull Cancer; 1982; 69(4):387-92. PubMed ID: 7150794
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adjusted significance levels for subgroup analyses in clinical trials.
    Spiessens B; Debois M
    Contemp Clin Trials; 2010 Nov; 31(6):647-56. PubMed ID: 20832503
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A group sequential approach to evaluation of bridging studies.
    Hsiao CF; Xu JZ; Liu JP
    J Biopharm Stat; 2003 Nov; 13(4):793-801. PubMed ID: 14584723
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Flexible design clinical trial methodology in regulatory applications.
    Hung HM; Wang SJ; O'Neill R
    Stat Med; 2011 Jun; 30(13):1519-27. PubMed ID: 21344470
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical trial designs--made to order.
    Andersen JS
    J Biopharm Stat; 1996 Nov; 6(4):515-22. PubMed ID: 8969983
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adaptive seamless designs: selection and prospective testing of hypotheses.
    Jennison C; Turnbull BW
    J Biopharm Stat; 2007; 17(6):1135-61. PubMed ID: 18027222
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interim analyses and early termination of clinical trials.
    Choi SC
    J Biopharm Stat; 1997 Nov; 7(4):533-43. PubMed ID: 9358327
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Two-stage adaptive designs with correlated test statistics.
    Hommel G; Lindig V; Faldum A
    J Biopharm Stat; 2005; 15(4):613-23. PubMed ID: 16022167
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vasopressors and the search for the optimal trial design.
    Maharaj R
    Contemp Clin Trials; 2011 Nov; 32(6):924-30. PubMed ID: 21807122
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A simple and flexible graphical approach for adaptive group-sequential clinical trials.
    Sugitani T; Bretz F; Maurer W
    J Biopharm Stat; 2016; 26(2):202-16. PubMed ID: 25372071
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
    Shimura M; Maruo K; Gosho M
    Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Improving Probabilities of Correct Interim Decision in Population Enrichment Designs.
    Götte H; Donica M; Mordenti G
    J Biopharm Stat; 2015; 25(5):1020-38. PubMed ID: 24914474
    [TBL] [Abstract][Full Text] [Related]  

  • 80. On the designs of thorough QT/QTc clinical trials.
    Tsong Y
    J Biopharm Stat; 2013; 23(1):43-56. PubMed ID: 23331220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.